Key Highlights
- Guggenheim Securities increased its Eli Lilly price target from $1,235 to $1,273 while reaffirming its Buy recommendation
- Shares currently trading near $1,189, reflecting a 51% gain over the trailing 12-month period
- Firm projects second-quarter revenue of $20.66 billion, surpassing Street estimates of $20.55 billion
- Foundayo obesity medication sales anticipated to gain traction following June consumer marketing launch
- Probability of success for pipeline drug retatrutide upgraded to 85%, with potential annual sales reaching $25 billion by 2035
Guggenheim Securities analyst Seamus Fernandez increased his valuation on Eli Lilly shares to $1,273 from a previous $1,235 target on Monday, while maintaining the firm’s Buy recommendation. The revised target represents approximately 7% potential upside from the stock’s current level of roughly $1,189.
Over the past year, LLY shares have surged 51%, pushing the pharmaceutical company’s market capitalization to approximately $1.06 trillion. The stock is hovering close to its 52-week peak of $1,249.
Fernandez revised his financial model in anticipation of Eli Lilly’s second-quarter financial results, scheduled for release on August 5, incorporating updated prescription data and currency exchange rate assumptions. The investment firm now forecasts quarterly revenue of $20.66 billion, exceeding the consensus estimate of $20.55 billion from Wall Street analysts.
Domestic prescription volumes for tirzepatideāmarketed under the brand names Zepbound for obesity and Mounjaro for diabetesāremain robust, supporting Guggenheim’s optimistic second-quarter projections. The company’s revenue has expanded 47% on a year-over-year basis, reaching $72.25 billion in the trailing twelve-month period.
Obesity Drug Portfolio Garners Investor Focus
Eli Lilly’s recently launched oral obesity treatment Foundayo, which debuted in April, prompted Guggenheim to moderately reduce its immediate-term sales projections due to the initial launch phase. Nevertheless, analysts highlighted that widespread consumer advertising campaigns only commenced in early June, suggesting significant potential for accelerated sales growth in coming quarters.
Guggenheim anticipates the upcoming second-quarter earnings conference call will emphasize guidance increases, geographic expansion strategies, and potential Medicare reimbursement coverage for the company’s anti-obesity medications.
Regarding the development pipeline, Guggenheim elevated its success probability for retatrutideāa next-generation obesity treatment candidateāfrom 70% to 85%. This adjustment follows encouraging clinical data unveiled at the American Diabetes Association scientific sessions. The firm’s analysts project that retatrutide could generate more than $25 billion in annual revenue by 2035.
Widespread Wall Street Endorsement
Guggenheim’s bullish stance aligns with sentiment across the analyst community. Truist Securities elevated its LLY price objective to $1,370, highlighting robust domestic prescription growth for both Zepbound and Mounjaro. Cantor Fitzgerald advanced its target to $1,350 alongside an Overweight rating.
RBC Capital maintained its Outperform rating with a $1,250 valuation, emphasizing favorable growth trajectories.
Among 22 Wall Street analysts covering the stock, LLY carries a consensus Strong Buy rating, comprising 20 Buy ratings and two Hold ratings issued within the most recent three-month period.
The average price target among this analyst group stands at $1,294.06, suggesting approximately 17% upside potential from present trading levels.
Eli Lilly plans to showcase 16 research abstracts at the 2026 Alzheimer’s Association International Conference scheduled in London, featuring data on its Alzheimer’s therapy Kisunla and associated patient outcome studies.
The pharmaceutical company will announce its second-quarter financial results on August 5.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
